Clinical Trials Logo

Filter by:
NCT ID: NCT02095314 Completed - Healthy Clinical Trials

Antibody Persistence, Immune Response and Safety After Doses of Pentabio Vaccine

Start date: March 2014
Phase: Phase 2/Phase 3
Study type: Interventional

Measure antibody persistence prior to booster administration of Pentabio vaccine.

NCT ID: NCT02094703 Recruiting - Clinical trials for Urinary Tract Infection

The Efficacy of Solifenacin Succinate as Adjuvant Therapy for Urinary Tract Infection in Females

Start date: April 2013
Phase: Phase 4
Study type: Interventional

The efficacy of Solifenacin Succinate 5 mg as adjuvant therapy and levofloxacin (500 mg) for short-term treatment to reduce symptoms in patients with symptomatic non complicated urinary tract infection in females.

NCT ID: NCT02093286 Completed - Healthy Clinical Trials

Safety Profile Following Pentabio Vaccination in Indonesian Infants

Start date: May 2014
Phase: N/A
Study type: Observational

To assess any serious systemic reaction within 30 minutes after Pentabio immunization

NCT ID: NCT02093273 Completed - Healthy Clinical Trials

Evaluation on Immunogenicity and Safety Profile of Trivalent OPV (tOPV Bio Farma)

Start date: May 2013
Phase: Phase 2
Study type: Interventional

The objective of this study is to compare the antibody response 30 days after two doses of t OPV

NCT ID: NCT02093260 Completed - Healthy Clinical Trials

Immunogenocity and Safety of Flubio (Influenza HA) Vaccine in Infants and Children (Bridging Study)

Start date: May 2014
Phase: Phase 2/Phase 3
Study type: Interventional

To Asses the Immunogenicity and Safety of Flubio (Influenza HA) Vaccine in Infants and Children (Bridging Study)

NCT ID: NCT02078271 Active, not recruiting - Child Development Clinical Trials

Food-Based Intervention and Psychosocial Stimulation to Improve Growth & Development of < 24 Month Indonesian Children

FIRST
Start date: January 2011
Phase: Phase 3
Study type: Interventional

WHO has urged all developing countries to develop programmes to improve complementary-feeding (CF) practices because of their importance for optimal growth, development and health of infants and young children While supplementation programmes and/or highly-fortified "super-foods" have limited success in improving CF-practices in disadvantaged environments, population-specific food-based dietary guidelines (FBDG), based on locally-available foods and requires minimal changes to local food pattern, will enhance the chances of programme success. Our previous study was able to identify the need for, potential and finally develop FBDG for CF of 6-8mo and 9-11mo infants using combined linear-and-goal programming approach (LP approach). This research is therefore being made to support the next phase of the study i.e. to assess the efficacy of FBDG, for improving CF/dietary-practices and growth in <24mo children (window of opportunity). As growth and development is inter-related, home-based stimulation will be included in this trial to see the effect on child development. While studies have shown that stimulation at early age benefits children through their late adolescence; evidence from Indonesia is lacking. This study therefore aims to see the effect on growth and development of community trial using food-based dietary guideline and stimulation. It is expected that findings from this study will provide scientific evidence as the basis for program formulation.

NCT ID: NCT02066961 Completed - Prostate Cancer Clinical Trials

A Study to Describe Patterns of Care and Outcomes of Men Who Are at High Risk After Experiencing Biochemical Failure Following Definitive Prostate Cancer Therapy, Men With Castration-resistant Prostate Cancer and Men With Metastatic Prostate Cancer

ASPIRE-PCa
Start date: December 31, 2013
Phase:
Study type: Observational

The purpose of this study is to describe patterns in disease management and to describe clinical outcomes, as well as to identify factors influencing physician treatment decisions including reason(s) for treatment choices and trigger(s) for treatment changes and to document healthcare resource utilization used to manage treatment-related complications.

NCT ID: NCT02054195 Completed - Clinical trials for Intra-uterine Device Complication

Training Model on Insertion Techniques for Postplacental Intra Uterine Device

PTKP
Start date: August 2012
Phase: Phase 4
Study type: Interventional

This study aimed to compare special guided training model with standard procedure on insertion technique for post-placental intra uterine device that provides IUD location close enough to fundal part of uterus to prevent expulsion

NCT ID: NCT02033681 Enrolling by invitation - Ischemia Clinical Trials

Optimal Time Delay of Epinephrine Injection With "One-per-mil" Tumescent Solution

Start date: September 2013
Phase: N/A
Study type: Interventional

The aim of this study is to know the characteristic of "one-per-mil" tumescent solution in regards of the optimal time delay to achieve optimal visualization of operation field in hand and digit surgery. Hypothesis: 1. Epinephine in "one-per-mil" concentration by tumescent injection technique will provide faster decrease in oxygen saturation compared to normal saline solution injected by tumescent technique. 2. Epinephrine in "one-per-mil" concentration by tumescent injection technique will provide effectiveness in vasoconstriction longer than 10 minutes as the optimal time delay. 3. Epinephine in "one-per-mil" concentration by tumescent injection technique causes no finger necrosis as normal saline solution injected by tumescent technique.

NCT ID: NCT02015273 Completed - Growth Disorders Clinical Trials

To Assess the Level of Adherence of Subjects Receiving SAIZEN® Via Easypod™ (ECOS Taiwan, Indonesia, Singapore)

ECOS TW ID SG
Start date: February 28, 2014
Phase:
Study type: Observational

This is an Multinational, Multicenter, Observational Study to evaluate Adherence and Long Term Outcomes of Therapy in pediatric subjects using easypod™ electromechanical device for growth hormone treatment and to assess the level of adherence of subject receiving SAIZEN® via easypod™.